Stem Cell Therapy for Peripheral Neuropathy

Peripheral neuropathy — burning, numbness, tingling and pain, most often in the feet — is common, difficult to treat, and frequently under-managed. Conventional options help some people and not others.

That gap is where stem cell marketing sits, usually at $8,000–$20,000 for a course of intravenous infusions.

What the evidence shows

The honest answer is that there is not much of it.

Published work consists largely of small studies, case series, and early-phase trials, most in diabetic peripheral neuropathy, and most without a placebo control. Some report improvements in symptom scores and nerve conduction measures. Others show no meaningful change.

There is currently no high-quality randomised controlled evidence establishing that stem cell therapy improves peripheral neuropathy in humans. No stem cell product is FDA approved for it.

That is not the same as saying it cannot work. Neuropathy involves inflammation and impaired microvascular supply, both of which are plausible targets for cell signalling effects. The biological rationale is more coherent than for several other marketed indications. But plausible mechanism is not evidence of benefit, and the field has repeatedly produced plausible mechanisms that failed in controlled trials.

Why neuropathy is especially hard to assess without a control group

Neuropathic symptoms fluctuate considerably — with blood glucose control, activity, sleep, temperature, and mood. Pain scores are subjective. And neuropathy responds strongly to placebo: in trials of drugs for neuropathic pain, placebo groups routinely report substantial improvement.

Any clinic reporting that most patients improve, without a placebo comparison, has measured something real but has not shown what caused it.

The delivery question

Most clinics administer intravenous infusions for neuropathy. For cells delivered intravenously to affect nerves in the feet, they would need to survive circulation, reach the relevant tissue, and act there. Most infused mesenchymal cells are cleared by the lungs within hours.

Ask the clinic to explain the mechanism by which an IV infusion reaches your peripheral nerves. The answer is informative.

Treatments with better evidence

For diabetic neuropathy, the intervention with the strongest evidence is unglamorous: tight glycaemic control, which slows progression and is the only approach shown to affect the underlying disease.

Beyond that:

• Duloxetine, pregabalin, gabapentin, amitriptyline — first-line pharmacological options with randomised evidence
• Topical capsaicin or lidocaine for localised symptoms
• Structured exercise — evidence for improving symptoms and nerve function
• Vitamin B12 correction where deficiency is present
• Alcohol reduction where relevant
• Podiatric care — foot ulcer prevention matters more than symptom relief for long-term outcomes

Many patients arrive at stem cell clinics without having systematically tried the pharmacological options at adequate doses. That is worth checking before spending $15,000.

Find the cause first

Neuropathy has many causes: diabetes, B12 deficiency, alcohol, chemotherapy, thyroid disease, autoimmune conditions, inherited disorders, and infections. Some are treatable, and treating the cause works better than treating the symptom.

If you have not had a full workup from a neurologist, that comes before any consideration of cell therapy.

Questions for your clinic

1. Which randomised controlled trial supports this for my type of neuropathy?
2. By what mechanism does an intravenous infusion reach my peripheral nerves?
3. What objective measure — nerve conduction study, quantitative sensory testing — do you use, and what were your results at twelve months?
4. Has my underlying cause been identified and treated?

Sources

1. International Society for Stem Cell Research — Patient Handbook on Stem Cell Therapies.
2. US Food and Drug Administration — Approved Cellular and Gene Therapy Products.
3. American Diabetes Association — standards of care for diabetic neuropathy management.

---